Alzheimer’s still has no cure, but with the help of drugs we can help & manage the symptoms of this disease. Alzheimer’s treatment is a high risk treatment, high reward market.
Alzheimer’s disease (AD) is a progressive neurodegenerative disease that is characterized by the memory loss, cognitive impairment, and functional decline. During the early stages of this disease, sleep disturbances and forgetfulness are the first showing symptoms that occurs in a patient. It is a progressive disease as it gradually increases with time and damages maximum part of the brain and finally it ruptures the brain cells and nerves. The major concern regarding Alzheimer’s disease is the detection of the condition in the patient.
In 2017, the market has been completely changed by the introduction of the disease-modifying therapies and innovative diagnostic technologies for Alzheimer’s. The potential of new drugs and diagnostics in this market is enormous and is given the high prevalence of AD. All of the prescribed medications have been currently approved to treat the Alzheimer’s in early to moderate stages with a class of drugs called cholinesterase inhibitors. These inhibitors are prescribed to treat symptoms that are related to memory, thinking, language, judgment and other thought processes.
Many of the prescribed drugs are currently being approved by the U.S. Food and Drug Administration (FDA) to treat the patients who have been diagnosed with Alzheimer’s. The Food and Drug Administration (FDA) has also approved many specific drugs to treat the Alzheimer’s and are thus helpful in curing the symptoms. According to the latest Dementia India report, a study by the Alzheimer’s and Related Disorder Society of India (ARDSI) revealed that there are nearly 3.7 million people affected by dementia in India. Alzheimer’s drug market in India is largely covered by the domestic and foreign generic drug developers.
A report by Market Intelligence Firm, says that the Alzheimer’s market accounted for USD 5.7 billion in 2015, growing with a CAGR of 10.3%. Due to drug patent expirations and many generics entering the market, the market is expected to see a declination by the year 2017. The market is anticipated to grow, driven by the disease-modifying drugs, and the vast last-stage pipeline drugs. The prevalence of Alzheimer’s in the United States is almost 5 million. Moreover, owing to the increasing aging population, it is expected to grow further globally.
The main hurdle for Alzheimer’s diagnosis and drugs market is there are lack of substitute markers in the market for drug discovery and drug development, and it is a highly expensive process which is coupled with uncertainty issues. The treatment of Alzheimer’s is little tricky affair. There is no diagnosis that can accurately determine whether a person is suffering from Alzheimer or not. Currently, there is no specific test that can confirm the presence of Alzheimer.